Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S0600||SWOG||Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX; OPTIMOX or XELOX||Adult CIRB - Late Phase Emphasis||Completed|
|ARST0921||COG||A Randomized Phase II Trial of Bevacizumab (IND# 7921; Avastin) and Temsirolimus (IND# 61010; Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma: A Groupwide Phase II Study||Pediatric CIRB||Completed|
|NSABP-R-04||NSABP||A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-80303||CALGB||A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC #704865 IND# 7921) Versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-33||NSABP||A Randomized; Placebo-Controlled; Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3N0-1M0 Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy||Adult CIRB - Late Phase Emphasis||Completed|
|AAML07P1||COG||A Phase II Pilot Study of Bortezomib (PS-341; Velcade; IND# 58;443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent; Refractory or Secondary Acute Myeloid Leukemia||Pediatric CIRB||Completed|
|S0421||SWOG||Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|SWOG-9007||SWOG||Cytogenetic Studies in Leukemia Patients||Adult CIRB - Late Phase Emphasis||Completed|
|E2499||ECOG||Randomized Phase III Trial of Rituximab (NSC #687451) and Autologous Stem Cell Transplantation for B Cell Diffuse Large Cell Lymphoma||Adult CIRB - Late Phase Emphasis||Completed|
|AALL0622||COG||Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969; NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL): A Groupwide Phase II/III Study||Pediatric CIRB||Completed|